This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

ResMed's CEO Discusses CEO Discusses F2Q2012 Results - Earnings Call Transcript

At this time, I would like to turn the call over to Dr. Peter Farrell, ResMed’s Chairman and CEO. Dr. Farrell, please go ahead sir.

Peter Farrell

Thanks Stacy, and thanks everyone for joining us. I’ll begin as usual with a short summary and then pass the call over to Brett Sandercock, ResMed’s CFO and then we’ll go into a Q&A.

So first, the financials. We finished with a very solid quarter. Global revenues in the second quarter of 2012 grew 9% to $333 million, which was also up 9% on a constant currency basis. Revenues in the Americas grew by an encouraging 12% to $182.5 million and ROW revenue increased by 5% at the headline and also in constant currency terms to $150.2 million.

GAAP EPS increased 14% to $0.42 for the quarter and I believe consensus was $0.38 which we comfortably beat and if we exclude the amortization of acquired intangibles, EPS was a record $0.44which we would suggest represents effective management and operational excellence and efficiency.

With the respect to product performance, masks continued to perform well across the globe and we continue to take market share. The three masks, new masks in the FX trilogy that is the Quattro FX, the Mirage FX and the Swift FX as well as the four versions of these masks continue to do extremely well and with the success of the Mirage, we are gaining additional share in nasal masks category which recently had been a week spot for us.

And we just launched the Swift FX [Bella] mask giving female patients the choice of how they wear the masks since it offers hair management solutions in brief and we expect this to also improve patient compliance and in brief the mask has a loop which wraps around the ears without any straps on the forehead or head itself.

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,776.12 -200.19 -1.11%
S&P 500 2,067.89 -18.35 -0.88%
NASDAQ 4,900.8850 -46.5560 -0.94%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs